Sericea Stallings-Smith1, Kevin R Krull1, Tara M Brinkman1, Melissa M Hudson2, Rohit P Ojha3. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. 2. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: rohit.ojha@stjude.org.
Abstract
BACKGROUND: Pediatric cancer patients who received blood transfusions were potentially exposed to hepatitis C virus (HCV) prior to second-generation HCV screening of blood products in 1992. Limited evidence is available about long-term incident cirrhosis in this population. OBJECTIVES: We aimed to estimate the overall and sex-specific incidence of cirrhosis among HCV-seropositive survivors of pediatric cancer. STUDY DESIGN: We identified 113HCV-seropositive pediatric cancer patients treated at St. Jude Children's Research Hospital between 1962 and 1997, who survived ≥5 years post-diagnosis, and were followed through 2014. Our outcome was cirrhosis determined by liver biopsy or diagnostic imaging. We used a competing-risk framework to estimate the overall and sex-specific cumulative incidence and 95% confidence limits (CL) of cirrhosis at 10-year follow-up intervals. RESULTS: The median duration of follow-up was 30 years (interquartile range=28-36) post-cancer diagnosis. Cumulative incidence of cirrhosis increased at each 10-year interval from 0% after 10 years to 13% after 40 years (Ptrend<0.001). The median age at diagnosis of cirrhosis was 30 years (interquartile range=24-38). We observed a linear trend in incidence for males (Ptrend<0.001), with a cumulative incidence of 18% (95% CL: 6.1%, 34%) after 40 years. The cumulative incidence for females was 6.5% (95% CL: 0.42%, 26%) after 40 years, but we did not observe a linear trend (Ptrend=0.99). CONCLUSION: Our results suggest that the incidence of cirrhosis is similar between HCV-seropositive pediatric cancer survivors and the general population given similar duration of follow-up, but survivors may be diagnosed with cirrhosis at an earlier age.
BACKGROUND:Pediatric cancerpatients who received blood transfusions were potentially exposed to hepatitis C virus (HCV) prior to second-generation HCV screening of blood products in 1992. Limited evidence is available about long-term incident cirrhosis in this population. OBJECTIVES: We aimed to estimate the overall and sex-specific incidence of cirrhosis among HCV-seropositive survivors of pediatric cancer. STUDY DESIGN: We identified 113HCV-seropositive pediatric cancer patients treated at St. Jude Children's Research Hospital between 1962 and 1997, who survived ≥5 years post-diagnosis, and were followed through 2014. Our outcome was cirrhosis determined by liver biopsy or diagnostic imaging. We used a competing-risk framework to estimate the overall and sex-specific cumulative incidence and 95% confidence limits (CL) of cirrhosis at 10-year follow-up intervals. RESULTS: The median duration of follow-up was 30 years (interquartile range=28-36) post-cancer diagnosis. Cumulative incidence of cirrhosis increased at each 10-year interval from 0% after 10 years to 13% after 40 years (Ptrend<0.001). The median age at diagnosis of cirrhosis was 30 years (interquartile range=24-38). We observed a linear trend in incidence for males (Ptrend<0.001), with a cumulative incidence of 18% (95% CL: 6.1%, 34%) after 40 years. The cumulative incidence for females was 6.5% (95% CL: 0.42%, 26%) after 40 years, but we did not observe a linear trend (Ptrend=0.99). CONCLUSION: Our results suggest that the incidence of cirrhosis is similar between HCV-seropositive pediatric cancer survivors and the general population given similar duration of follow-up, but survivors may be diagnosed with cirrhosis at an earlier age.
Authors: Pierre Pradat; Nicolas Voirin; Hans Ludger Tillmann; Michèle Chevallier; Christian Trépo Journal: Liver Int Date: 2007-04 Impact factor: 5.828
Authors: Sharon Castellino; Shelly Lensing; Caroline Riely; Shesh N Rai; Rene Davila; Randall T Hayden; Jackie Fleckenstein; Mark Levstik; Shari Taylor; Patrick J Dean; Sarah Kippenbrock; Jennifer Pope; Jeanne Carr; Donald K Strickland; Melissa M Hudson Journal: Blood Date: 2003-12-18 Impact factor: 22.113
Authors: Juan A Pineda; José A García-García; Manuela Aguilar-Guisado; María J Ríos-Villegas; Josefa Ruiz-Morales; Antonio Rivero; José del Valle; Rafael Luque; Jesús Rodríguez-Baño; Mercedes González-Serrano; Angela Camacho; Juan Macías; Israel Grilo; Jesús M Gómez-Mateos Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: Meagan Lansdale; Sharon Castellino; Neyssa Marina; Pamela Goodman; Melissa M Hudson; Ann C Mertens; Stephanie M Smith; Wendy Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Adrienne Studaway; Rohit P Ojha; Tara M Brinkman; Nan Zhang; Malek Baassiri; Pia Banerjee; Matthew J Ehrhardt; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2017-07-25 Impact factor: 6.860